Clarity Pharmaceuticals Ltd has released a press release.
Novel FAP-targeted radiopharmaceutical
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- S&P DJI Announces December 2024 Quarterly Rebalance
- Last patient assessment completed for SARTATE trial
- First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
- Chairperson Address AGM
- Head-to-head IIT with SAR-bisPSMA
Later from Clarity Pharmaceuticals
- Clarity receives U.S. FDA Fast Track Designation
- Clarity to present COBRA and CLARIFY abstracts
- Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
- Clarity receives US FDA FTD for the treatment of mCRPC
- Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals